1.85

0.54% +0.01

SILO Pharma Inc (SILO)

Overview News Price History Financials Discussions Forecast Stock Split

SILO Pharma Inc stock is currently priced at $1.85, with a 24-hour trading volume of 8,376. It has seen a +0.54% increased in the last 24 hours and a -5.13% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.85 pivot point. If it approaches the $1.92 resistance level, significant changes may occur.

Previous Close:

$1.84

Open:

$1.79

24h Volume:

8,376

Market Cap:

$5.26M

Revenue:

$72,100

Net Income/Loss:

$-4.24M

P/E Ratio:

-1.1012

EPS:

-1.68

Net Cash Flow:

$-3.20M

1W Performance:

-1.60%

1M Performance:

-5.13%

6M Performance:

+21.71%

1Y Performance:

-12.74%

1D Range:

$1.79

$1.8799

52W Range:

$1.2162

$3.05

SILO Pharma Inc Stock (SILO) Company Profile

Name

SILO Pharma Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

718 400 9031

Address

560 Sylvan Avenue, Suite 3160, Englewood Cliffs

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SILO's Discussions on Twitter

SILO Pharma Inc Stock (SILO) Latest News

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

GlobeNewswire Inc.

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic

GlobeNewswire Inc.

Citizens And 2 Other Stocks Under $3 Insiders Are Buying

Benzinga

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying

Benzinga

Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic

GlobeNewswire Inc.

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

GlobeNewswire Inc.

SILO Pharma Inc Stock (SILO) Financials Data

SILO Pharma Inc (SILO) Revenue 2024

SILO reported a revenue (TTM) of $72.10 thousand for the quarter ending September 30, 2023, a 0.00% decline year-over-year.

SILO Pharma Inc (SILO) Net Income 2024

SILO net income (TTM) was -$4.24 million for the quarter ending September 30, 2023, a -27.23% decrease year-over-year.

SILO Pharma Inc (SILO) Cash Flow 2024

SILO recorded a free cash flow (TTM) of -$3.20 million for the quarter ending September 30, 2023, a +5.46% increase year-over-year.

SILO Pharma Inc (SILO) Earnings per Share 2024

SILO earnings per share (TTM) was -$1.40 for the quarter ending September 30, 2023, a +7.28% growth year-over-year.

Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. It is developing solutions to address various underserved conditions. The company seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders. The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.